



OPEN

Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Soheil Hassanipour¹, Morteza Arab-Zozani¹, Bahman Amani¹, Forough Heidarzad¹,
Mohammad Fathalipour¹ & Rudolph Martinez-de-Hoyo¹

Addendum to: *Scientific Reports* <https://doi.org/10.1038/s41598-021-90551-6>, published online 26 May 2021

In the original version of this Article we included the data reported in a preprint by Dabbous et al. entitled "Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial", which was later published¹. After publication of our Article it was brought to our attention that Dabbous et al.' paper had subsequently been retracted². We have therefore repeated sub-analyses in which this study was originally included to establish the effect of the removal of this data from the review.

The results of the analyses reported in the original Figures 3 and 7, updated for removal of Dabbous et al. data, are shown below (Figure 1 and 2, respectively).


Viral clearance

The result of the updated meta-analysis show that viral clearance 7, 10, and 14 days after hospitalization is not statistically different between the Favipiravir and control groups (RR= 1.13, 95% CI: 0.83-1.53; P= 0.425, I2= 66.0%, P= 0.019 for 7 days; RR= 1.04, 95% CI: 0.93-1.16; P= 0.454, I2= 0.0%, P= 0.973 for 10 days; RR= 1.11, 95% CI: 0.91-1.36; P= 0.264, I2= 60.9%, P= 0.077 for 14 days) (Fig. 1).

Mortality


Based on the updated meta-analysis, the mortality rate in the Favipiravir group was approximately 23% lower than in the control group, but this finding is not statistically significant (RR= 0.77, 95% CI: 0.26-2.19; P= 0.625, I2= 0.0%, P= 0.585) (Fig. 2).

Published online: 01 February 2022



Meta Analysis

Figure 1. The updated meta-analysis of viral clearance of Favipiravir on COVID-19 patients after removal of Dabbous et al. data (Orange diamond: summary of sub groups; Red diamond: summary of total).




Meta Analysis

Figure 2. The updated meta-analysis of mortality of Favipiravir on COVID-19 patients after removal of Dabbous et al. data (Red diamond: summary of total).

References

1. Dabbous, H. M. *et al.* RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. *Sci. Rep.* **11**, 7282 (2021).
2. Dabbous, H. M. *et al.* Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. *Sci. Rep.* **11**, 18983 (2021).

 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022